The pharmacogenetics of symptom response to Antipsychotic drugs

Psychiatry Investigation

Volumn 9, Issue 1, 2012, Pages 1-7

  Reynolds, Gavin P ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Genes; Negative symptoms; Polymorphisms; Positive symptoms; Schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE; GLUTAMIC ACID; ILOPERIDONE; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN; SEROTONIN RECEPTOR;

ARTICLE; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEREDITY; HUMAN; NEGATIVE SYNDROME; NERVE CELL DIFFERENTIATION; NEUROTRANSMISSION; NONHUMAN; PHARMACOGENETICS; POSITIVE SYNDROME; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84857948217     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2012.9.1.1     Document Type: Article

References (59)

1. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011;378:1306-1315.
2. Vojvoda D, Grimmell K, Sernyak M, Mazure CM. Monozygotic twins concordant for response to clozapine. Lancet 1996;347:61.
3. Mata I, Madoz V, Arranz MJ, Sham P, Murray RM. Olanzapine: concordant response in monozygotic twins with schizophrenia. Br J Psychiatry 2001;178:86.
4. Reynolds GP. The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discov Today 2007;12:953-959.
5. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
6. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 2010; 128:419-432.
7. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011;11:59-67.
8. Reynolds GP, Templeman LA, Godlewska BR. Pharmacogenetics of schizophrenia. Expert Opin Pharmacother 2006;7:1429-1440.
9. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161:780-796.
10. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010;167:763-772.
11. Hwang R, Zai C, Tiwari A, Muller DJ, Arranz MJ, Morris AG, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine tr-eatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010;10: 200-218.
12. Xuan J, Zhao X, He G, Yu L, Wang L, Tang W, et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone resp-onse: a pharmacogenetic study. Neuropsychopharmacology 2008;33: 305-311.
13. Xu MQ, St Clair D, Feng GY, Lin ZG, He G, Li X, et al. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet Genomics 2008;18:449-457.
14. Zhang A, Xing Q, Wang L, Du J, Yu L, Lin Z, et al. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics 2007;8:1337-1345.
15. Serretti A, Drago A, De Ronchi D. HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem 2007;14:2053-2069.
16. Benmessaoud D, Hamdani N, Boni C, Ramoz N, Hamon M, Kacha F, et al. Excess of transmission of the G allele of the-1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 2008;8:40.
17. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.
18. Dolzan V, Serretti A, Mandelli L, Koprivsek J, Kastelic M, Plesnicar BK. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1562-1566.
19. Wang L, Yu L, He G, Zhang J, Zhang AP, Du J, et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett 2007;414:1-4.
20. Lee HY, Kim DJ, Lee HJ, Choi JE, Kim YK. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with ch-aracteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:276-280.
21. Mossner R, Schuhmacher A, Kuhn KU, Cvetanovska G, Rujescu D, Zill P, et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 2009;19:91-94.
22. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symp-tom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 2006;163:1826-1829.
23. Wang L, Fang C, Zhang A, Du J, Yu L, Ma J, et al. The--1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol 2008;22:904-909.
24. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006;78:815-826.
25. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 2003;23:8788-8799.
26. Vazquez-Bourgon J, Arranz MJ, Mata I, Pelayo-Teran JM, Perez-Iglesias R, Medina-Gonzalez L, et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res 2010;175:189-194.
27. Adams DH, Close S, Farmen M, Downing AM, Breier A, Houston JP. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol 2008;23:267-274.
28. Meary A, Brousse G, Jamain S, Schmitt A, Szoke A, Schurhoff F, et al. Ph-armacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene. Am J Med Genet B Neu-ropsychiatr Genet 2008;147B:491-494.
29. Schuhmacher A, Mossner R, Quednow BB, Kuhn KU, Wagner M, Cvetanovska G, et al. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics 2009;19:843-851.
30. Silver H. Selective serotonin re-uptake inhibitor augmentation in the tr-eatment of negative symptoms of schizophrenia. Expert Opin Pharma-cother 2004;5:2053-2058.
31. Bertolino A, Caforio G, Blasi G, Rampino A, Nardini M, Weinberger DR, et al. COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res 2007;95:253-255.
32. Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 2009;9:311-318.
33. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF, et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004;56:677-682.
34. Bishop JR, Ellingrod VL, Moline J, Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 2005;77:253-260.
35. Bishop JR, Miller DD, Ellingrod VL, Holman T. Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia. Hum Psychopharmacol 2011. in press.
36. Zuo L, Luo X, Krystal JH, Cramer J, Charney DS, Gelernter J. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics 2009;19:437-446.
37. Mossner R, Schuhmacher A, Wagner M, Lennertz L, Steinbrecher A, Quednow BB, et al. The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms. Eur Arch Psychiatry Clin Neurosci 2011. in press.
38. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C (-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol 2004;7:501-506.
39. Goldberg TE, Kotov R, Lee AT, Gregersen PK, Lencz T, Bromet E, et al. The serotonin transporter gene and disease modification in psychosis: evidence for systematic differences in allelic directionality at the 5-HTTLPR locus. Schizophr Res 2009;111:103-108.
40. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomiz-ed comparison of olanzapine and risperidone. Biol Psychiatry 1999;46: 365-373.
41. Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004;18:340-345.
42. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000;355: 1615-1616.
43. Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ. The-1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 2004;56:406-410.
44. Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 2011;25:933-969.
45. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab To-xicol 2011;7:9-37.
46. Muller DJ, De Luca V, Sicard T, King N, Hwang R, Volavka J, et al. Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol 2005;15:525-531.
47. Anttila S, Kampman O, Illi A, Rontu R, Lehtimaki T, Leinonen E. Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. BMC Psychiatry 2007; 7:22.
48. Kohlrausch FB, Salatino-Oliveira A, Gama CS, Lobato MI, Belmonte-de-Abreu P, Hutz MH. G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics 2008;9:1429-1436.
49. Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP, et al. Ph-armacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009;17:946-957.
50. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 2010;83:108-121.
51. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006;67(Suppl 9):9-13.
52. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011;16:76-85.
53. McClay JL, Adkins DE, Aberg K, Bukszar J, Khachane AN, Keefe RS, et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 2011;36:616-626.
54. Webb BT, Sullivan PF, Skelly T, van den Oord EJ. Model-based gene selection shows engrailed 1 is associated with antipsychotic response. Pharmacogenet Genomics 2008;18:751-759.
55. Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I, Genius J, et al. Ho-mer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. J Psychiatr Res 2011;45: 234-241.
56. Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R, et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 2010;67:263-269.
57. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009;14:804-819.
58. Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009;70:801-809.
59. Fijal BA, Stauffer VL, Kinon BJ, Conley RR, Hoffmann VP, Witte MM, et al. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. J Clin Psychiatry 2011. in press.